A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia

NCT06776510 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia
Treatment

Interventions

DRUG: nicotinamide adenine dinucleotid/nicotinamide mononucleotide

Sponsor

Institute of Hematology & Blood Diseases Hospital, China